Propensity-weighted Long-term Risk of Urinary Adverse Events After Prostate Cancer Surgery, Radiation, or Both

被引:79
作者
Jarosek, Stephanie L. [1 ]
Virnig, Beth A. [2 ]
Chu, Haitao [3 ]
Elliott, Sean P. [1 ]
机构
[1] Univ Minnesota, Sch Med, Dept Urol, Minneapolis, MN 55455 USA
[2] Univ Minnesota, Sch Publ Hlth, Div Hlth Policy & Management, Minneapolis, MN 55455 USA
[3] Univ Minnesota, Sch Publ Hlth, Div Biostat, Minneapolis, MN 55455 USA
关键词
Outcomes research; Prostate cancer; Reconstructive urology; SEER-Medicare; Urinary adverse effects; MARGINAL STRUCTURAL MODELS; DOSE-RATE BRACHYTHERAPY; SEER-MEDICARE DATA; RADICAL PROSTATECTOMY; COMPLICATIONS; RADIOTHERAPY; THERAPY; MORBIDITY; GENITOURINARY; POPULATION;
D O I
10.1016/j.eururo.2014.08.061
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Background: Prostate cancer is the second most common cancer in men and has high survivorship, yet little is known about the long-term risk of urinary adverse events (UAEs) after treatment. Objective: To compare the long-term UAE incidence across treatment and control groups. Design, setting, and participants: Using a matched-cohort design, we identified elderly men treated with external-beam radiotherapy (EBRT; n = 44 318), brachytherapy (BT; n = 14 259), EBRT+BT (n = 11 835), radical prostatectomy (RP; n = 26 970), RP+EBRT (n = 1557), or cryotherapy (n = 2115) for non-metastatic prostate cancer and 144 816 non-cancer control individuals from the population-based Surveillance, Epidemiology, and End Results-Medicare linked data from 1992-2007 with follow-up through 2009. Outcome measures and statistical analysis: The incidence of treated UAEs and time from cancer treatment to first UAE were analyzed in terms of propensity-weighted survival. Results: Median follow-up was 4.14 yr. At 10 yr, all treatment groups experienced higher propensity-weighted cumulative UAE incidence than the control group (16.1%; hazard risk [HR] 1.0), with the highest incidence for RP+EBRT (37.8%; HR 3.19, 95% confidence interval [CI] 2.79-3.66), followed by BT+EBRT (28.4%; HR 1.97, CI 1.85-2.10), RP (26.6%; HR 2.44, CI 2.34-2.55), cryotherapy (23.4%; HR 1.56, CI 1.30-1.87), BT (19.8%; HR 1.43, CI 1.33-1.53), and EBRT (19.7%; HR 1.11, CI 1.07-1.16). Bladder outlet obstruction was the most common event. Conclusions: Men undergoing RP, RP+EBRT, and BT+EBRT experienced the highest UAE risk at 10 yr, although UAEs accrued differently over extended follow-up. The significant background UAE rate among non-cancer control individuals yields a risk attributable to prostate cancer treatment that is 17% lower than prior estimates. Patient summary: We show that treatment for prostate cancer, especially combinations of two treatments such as radiation and surgery, carries a significant risk of urinary adverse events such as urethral stricture. This risk increases with time since treatment, emphasizing that treatments have long-term effects. (C) 2014 European Association of Urology. Published by Elsevier B.V. All rights reserved.
引用
收藏
页码:273 / 280
页数:8
相关论文
共 50 条
  • [11] Adjuvant Versus Salvage Radiation Therapy for Prostate Cancer Patients With Adverse Pathologic Features Comparative Analysis of Long-term Outcomes
    Mishra, Mark V.
    Scher, Eli D.
    Andrel, Jocelyn
    Margules, Andrew C.
    Hegarty, Sarah E.
    Trabulsi, Edouard J.
    Hyslop, Terry
    Den, Robert B.
    Lallas, Costas D.
    Gomella, Leonard G.
    Dicker, Adam P.
    Showalter, Timothy N.
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2015, 38 (01): : 55 - 60
  • [12] Factors influencing long-term urinary symptoms after prostate brachytherapy
    Stone, Nelson N.
    Winoker, Jared S.
    Kaplan, Steven A.
    Stock, Richard G.
    BJU INTERNATIONAL, 2018, 122 (05) : 831 - 836
  • [13] High risk localized and locally advanced prostate cancer: Long-term oncological outcomes after prostatectomy
    Miro-Padovani, M.
    da Costa, J. Batista
    Salomon, L.
    Ingels, A.
    De la Taille, A.
    PROGRES EN UROLOGIE, 2022, 32 (10): : 702 - 710
  • [14] Intensity-modulated radiation therapy for prostate cancer after rectal surgery: a single hospital long-term safety analysis
    Zhang, Shuang
    Nakamura, Kiyonao
    Aizawa, Rihito
    Akamatsu, Shusuke
    Mizowaki, Takashi
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2022, 27 (05) : 977 - 982
  • [15] The Effect of Perioperative Adverse Events on Long-Term Patient-Reported Outcomes After Lumbar Spine Surgery
    Ayling, Oliver G. S.
    Ailon, Tamir
    Street, John T.
    Dea, Nicolas
    McIntosh, Greg
    Abraham, Edward
    Jacobs, W. Bradly
    Soroceanu, Alex
    Johnson, Michael G.
    Paquet, Jerome
    Rasoulinejad, Parham
    Phan, Phillipe
    Yee, Albert
    Christie, Sean
    Nataraj, Andrew
    Glennie, R. Andrew
    Hall, Hamilton
    Manson, Neil
    Rampersaud, Y. Raja
    Thomas, Kenneth
    Fisher, Charles G.
    NEUROSURGERY, 2021, 88 (02) : 420 - 427
  • [16] Statin Use and Long-Term Mortality after Rectal Cancer Surgery
    Pourlotfi, Arvid
    Bass, Gary Alan
    Hulme, Rebecka Ahl
    Forssten, Maximilian Peter
    Sjolin, Gabriel
    Cao, Yang
    Matthiessen, Peter
    Mohseni, Shahin
    CANCERS, 2021, 13 (17)
  • [17] Dose-Effect Relationships for Adverse Events After Cranial Radiation Therapy in Long-term Childhood Cancer Survivors
    van Dijk, Irma W. E. M.
    Cardous-Ubbink, Mathilde C.
    van der Pal, Helena J. H.
    Heinen, Richard C.
    van Leeuwen, Flora E.
    Oldenburger, Foppe
    van Os, Rob M.
    Ronckers, Cecile M.
    Schouten-van Meeteren, Antoinette Y. N.
    Caron, Huib N.
    Koning, Caro C. E.
    Kremer, Leontien C. M.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2013, 85 (03): : 768 - 775
  • [18] Age at surgery, educational level and long-term urinary incontinence after radical prostatectomy
    Nilsson, Andreas E.
    Schumacher, Martin C.
    Johansson, Eva
    Carlsson, Stefan
    Stranne, Johan
    Nyberg, Tommy
    Wiklund, N. Peter
    Steineck, Gunnar
    BJU INTERNATIONAL, 2011, 108 (10) : 1572 - 1577
  • [19] Propensity-Weighted Survival Analysis of SBRT vs. Conventional Radiotherapy in Unfavorable Intermediate-Risk Prostate Cancer
    Andruska, Neal
    Fischer-Valuck, Benjamin W.
    Agabalogun, Temitope
    Carmona, Ruben
    Brenneman, Randall J.
    Huang, Yi
    Gay, Hiram A.
    Michalski, Jeff M.
    Baumann, Brian C.
    CLINICAL GENITOURINARY CANCER, 2022, 20 (02) : 123 - 131
  • [20] Androgen deprivation in prostate cancer and the long-term risk of fracture
    Ojeda, S.
    Lloret, M.
    Naranjo, A.
    Deniz, F.
    Chesa, N.
    Dominguez, C.
    Lara, P. C.
    ACTAS UROLOGICAS ESPANOLAS, 2017, 41 (08): : 491 - 496